EquityFlow
›
Companies
› Prilenia Therapeutics
Prilenia Therapeutics
Biotech
· Naarden, NL
Clinical-stage biotech developing treatments for neurodegenerative disorders.
Funding history
Date
Round
Amount
Nov 2021
Series B
Dutch-Israeli biotech Prilenia Therapeutics raised a USD 43M Series B led by Sands Capital, with Forbion and Morningside.
$43M
Investors
Amplitude Ventures
Forbion
Morningside
Sands Capital
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →